Latest filing published 13 Aug 2025 for Xeris Biopharma Holdings, Inc., €265k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Dawn Halkuff: trading record in brief
Dawn Halkuff (board member) discloses dealings in Xeris Biopharma Holdings, Inc. to SEC (Form 4). We count 6 filings; the first trade dates from 8 June 2022 and the latest from 12 August 2025.
In open-market terms, that means 1 purchase worth €9,127 on one side and 1 sale worth €265k on the other. The net balance comes to €256k on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 4 share grants. Since January 2025: no purchases and 1 sale on the market.
On 13 August 2025 came the latest disclosure, an open-market sale for €265k in Xeris Biopharma Holdings, Inc. The most recent open-market purchase was published on 21 November 2023, 1,085 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Dawn Halkuff
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 42,500 shares@ US$7.275996.7% of flowCommon StockSEC:0001867096-25-000138:0
- 50,000 shares0Common StockSEC:0001867096-25-000112:0
- 50,000 shares0Common StockSEC:0001867096-24-000103:0
- 5,410 shares@ US$1.84100.0% of flowCommon StockSEC:0001867096-23-000151:0Canonical exit: 18 Feb 2024 (T+90)
- 42,500 shares0Common StockSEC:0001867096-23-000097:0
- 15,000 shares0Common StockSEC:0001867096-22-000092:0
6 of 6 declarations
